Unmet Needs and Standards of Care in Multiple Myeloma
Brea C. Lipe, MD, discusses the evolving landscape of multiple myeloma treatment, highlighting the current abundance of drugs and the challenges associated with optimizing their use.
Brea C. Lipe, MD emphasizes the need to strike a balance between effective treatment and minimizing side effects, she acknowledges the persistent threat of patient mortality from the disease.
A key focus is on the evolving understanding of patient stratification, moving beyond the binary eligibility for transplant to recognizing distinct disease types—high-risk and standard-risk. This recognition prompts a concerted effort to determine the most effective treatment strategies for each category. In the context of newly diagnosed cases, there is a notable shift towards quad therapy, a progression from earlier doublet and triplet therapies. The speaker reflects on the historical belief that more drugs equate to better outcomes in myeloma treatment but acknowledges past challenges related to toxicity. However, advancements in drug effectiveness and targeting now allow for a reduction in side effects, making quad therapy a potential standard of care for eligible transplant patients in the newly diagnosed setting.
Dr. Lipe underscores the importance of finding treatments and improving existing ones to address the persistent mortality associated with the disease. The discourse reflects the dynamic nature of myeloma treatment, with a keen awareness of advancements and the imperative to adapt strategies to enhance patient outcomes.
Summary was AI-generated and edited for clarity.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
